WINDSOR, ON / ACCESSWIRE / April 19, 2016 / The Wealthy Biotech Trader (or "WBT"), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known known biotech, pharmaceutical and medical device stocks releasing impressive news and making market moves, would like to focus in on a few key industries that are experiencing tremendous investor interest which is resulting from major paradigm shifts currently underway.
One of the hottest spaces in the market continues to be biotech as controversy leaves the mainstream media (Hilary Clinton and Martin Shkreli). As the indexes and ETF's representing this industry look to be making a double bottom, the opportunity presents itself to potentially re-enter some of the smaller names in the space.
One hot name in the biotech space demanding a hard look remains Endonovo Therapeutics, Inc. (OTCQB: ENDV). ENDV has been steadily trading in the chart channel between $0.40 and $0.85, but appears to be mustering the energy in breaking the key level of $1.00, which would be a huge bullish sign for technical traders.
ENDV is developing a bioelectronic device, which if approved by the FDA, intends to treat acute liver failure (ALF) and other inflammatory conditions in vital organs. This non-implantable, non-invasive device would be used on patients to reduce inflammation and cell death, which are thought to be drivers of vital organ failure. Currently the only treatment for acute liver failure is a liver transplant. With fewer than 4,000 people developing this ailment per year in the United States, it should qualify as a rare disease whereby the company intends to apply for a humanitarian device exemption (HDE). An HDE could substantially reduce the time and cost for ENDV bringing this product to market.
ENDV's second platform utilizes its bioelectronics technology to expand and enhance stem cells for the creation of next-generation cell therapies. Additionally, ENDV is currently developing an off-the-shelf cell therapy for the treatment of Graft vs. Host Disease (GVHD). GVHD, which affects fewer than 200,000 people in the United States per year, is another potential rare disease the company previously announced plans to apply for as an Orphan Drug Designation.
TESLA FRENZY
At the beginning of the month Tesla Motors, Inc. (NASDAQ: TSLA) unveiled their much anticipated Model 3 which will sell for $35,000 and have a 300 mile per charge range - pretty much the biggest paradigm shift in personal transportation since the invention of the internal combustion engine. Within 1 week the company has pre-orders for over $12 Billion from customers that have not seen the car in person and would likely not receive deliver for over 1.5 years - insanity! That is 3X more revenue than the company did in all of 2015 combined. Smart investors took this as a cue to start investing in stocks that mine for the lithium that all of these many orders will require for their huge lithium ion battery packs
SOME INTERESTING PLAYERS IN THE LITHIUM SPACE
Lithium X Energy Corp. (OTCQB: LIXXF) is a lithium exploration and development company with a goal of becoming a low-cost supplier for the burgeoning lithium battery industry. Lithium X has entered into an agreement to advance the Sal de los Angeles lithium brine project in the prolific "Lithium Triangle" in mining friendly Salta Province, Argentina, a well-known salar with positive historical economics, grade and size. Lithium X is also exploring a large land package in Nevada's Clayton Valley, contiguous to the only producing lithium operation in North America - Silver Peak, owned and operated by Albemarle, the world's largest lithium producer. LIXXF's stock has made a great run over the past few months, but could have room to run based on the somewhat small market cap and how impressive the team behind it is.
Lithium Americas Corp. (OTCQX: LACDF) is the parent company of Minera Exar S.A., which is developing the Cauchari-Olaroz Lithium Project, located in Jujuy, Argentina, in a joint venture with SQM. Lithium Americas also is the parent to Lithium Nevada Corp., which owns one of the largest lithium resources in North America. This name has also had a huge run, but as the retail traders find out about how real the lithium complex is this time around, this industry is sure to be one of the major momentum trades for 2016.
GW PHARMA (NASDAQ: GWPH) PROVES IN CLINIC THAT CANABIS CAN TREAT SIESURES
The most paradigm shifting news on the medical side of the marijuana frenzy freight train to date has no doubt been the news of cannabis-focused GW Pharmaceuticals (NASDAQ: GWPH) reaching its primary endpoint in their clinical trial for the treatment of epilepsy (seizures). What this means is that cannabis-based medication has moved from being more of a joke to the medical community to a proven science, which real medicines WILL be derived from, for a number of indications. This is monumental.
Many of the cannabis/ marijuana stocks have sky rocketed on the heels of this news as the potential market size just keeps getting bigger and bigger. Two names to take a look at are TRTC and MSRT; both players that make the "picks and shovels" for the industry which is always a great business strategy.
Terra Tech Corp. (OTCQX: TRTC), through its wholly-owned subsidiary GrowOp Technology, specializes in controlled environment agricultural technologies. The company integrates best-of-breed hydroponic equipment with proprietary software and hardware to provide sustainable solutions for indoor agriculture enterprises and home practitioners. TRTC has made a parabolic upward move after the GWPH news and could have more of the same in store for Investors.
Aphria Inc., (CVE: APH) a company continued under the laws of the Province of Ontario and based in Leamington, Ontario, is in the business of producing, supplying and selling medical marijuana pursuant to the Marihuana for Medical Purposes Regulations (the "MMPR"). Under the MMPR, Health Canada is responsible for the oversight of commercial medical marijuana growers such as Aphria. Aphria's common shares are listed on the TSX Venture Exchange under the ticker symbol "APH", an exchange that is attracting many legitimate legal marijuana companies. APH’s stock chart has been stair-stepping higher since going public last year on the back of a flurry of positive corporate developments. One thing of not is that CEO of APH has an impressive past including growing the vitamin giant Jameson from a small player to a global behemoth, and that is what Investors are hoping Mr. Neufeld does with APH.
The Wealthy Biotech Trader is always researching new trade ideas which have the makings for large market moves. Traders are urged to follow our parent outlet, The Wealthy Venture Capitalist on social media (see below) to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports/ updates/ news through Twitter, Facebook, SMS as well as newswire.
GET BREAKING NEWS FROM US!
Click here to sign up for email trade alerts: http://eepurl.com/bUSa71
To receive text Message alerts: http://clk2.it/k7oF5z
Follow us on Twitter: @Wealthy_VC
Like us on Facebook: www.facebook.com/WealthyVC
Email: Info@WealthyVentureCapitalist.com
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Biotech Trader and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Sometimes human error can attribute to honest mistakes in reporting on issues regarding public companies and overall capital markets, and as such we are not responsible for the complete accuracy in these reports as the reader is required to verify all statements to ensure they are completely accurate. The Wealthy Biotech Trader encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Biotech Trader makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a 'safe harbor' in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security's previous day closing price and the high of day price during our promotional coverage.
The Wealthy Biotech Trader's parent company has been compensated $150,000 by Endonovo Therapeutics Inc. in the form of a 6 month restricted convertible promissory note, which will convert into a minimum of 2,300,000 common shares, and readers should understand that they will convert this note into common shares sell them into the market as soon as the statutory 144 hold period has lapsed.
Readers must visit our website at www.wealthyventurecapitalist.com in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this art.
SOURCE: The Wealthy Biotech Trader
ReleaseID: 438960
